Objective: To quantify the healthcare expenditures associated with potential oral glucocorticoid (OGC)-related adverse events (AEs) in patients with giant cell arteritis (GCA). Methods: Patients with GCA and ≥ 1 OGC prescription fill between 2009 and 2014 were identified from the MarketScan Commercial and Medicare Supplemental claims databases. Patients were stratified into four groups based on cumulative OGC dose (> 0 to ≤ 2607 mg, > 2607 to ≤ 4800 mg, > 4800 to ≤ 7200 mg, and > 7200 mg) during the 1-year follow-up period; incidence of potential AEs and AE-related direct healthcare costs in USD were assessed. Association between the log of cumulative OGC dose and AE-related direct healthcare costs was evaluated, adjusting for baseline characteristics. Results: Of 1602 patients with GCA included, 69% were women; the mean age was 73 years. The mean cumulative OGC dose was 5806 mg during the 1-year follow-up; most exposure occurred in the first 6 months. The proportion of patients with potential OGC-related AEs was 36.5% overall and increased as cumulative dose increased (30.7%-45.3% across dose groups). Unadjusted mean AE-related costs for patients with an AE was USD $12,818. In the multivariable model including all patients, increasing OGC dose was associated with increasing AE-related healthcare costs (cost ratio, 1.38 [95% CI, 1.16-1.64] per 1-unit increase in log of cumulative OGC dose [P < 0.001]). Mean (median)-predicted AE costs for the dose groups were USD $4389 ($2749) for > 0 to ≤ 2607 mg, USD $5176 ($3009) for > 2607 to ≤ 4800 mg, USD $5576 ($3633) for > 4800 to ≤ 7200 mg, and USD $6609 ($4447) for > 7200 mg.
Introduction
Giant cell arteritis (GCA), which affects medium-to largesized blood vessels, is the most common form of systemic vasculitis. 1 Clinical symptoms include headache, scalp tenderness, jaw claudication, and transient or permanent vision loss; 2 permanent vision loss occurs in an estimated 10% to 20% of patients with GCA. 3, 4 Markers of inflammation, including erythrocyte sedimentation rate and C-reactive protein levels, are elevated in patients with GCA. GCA is most common among women, particularly in those > 50 years of age. 5 The annual incidence and prevalence of GCA in the United States are estimated to be 18.9 per 100,000 and 228 per 100,000, respectively. 6, 7 The mainstay of treatment for GCA is immediate initiation of high-dose glucocorticoids (GCs), typically prednisolone, followed by tapering over many months after symptoms have resolved and erythrocyte sedimentation rate and C-reactive protein levels have normalized. 8 Tapering or discontinuation of GCs often leads to disease relapses requiring reinitiation of GCs, necessitating prolonged use and resulting in high cumulative doses over time. [9] [10] [11] Chronic GC exposure is associated with increased risk of adverse effects and comorbidities in patients with GCA, including infections, osteoporosis, fractures, cataract, glaucoma, and diabetes. 9, [11] [12] [13] [14] Increased cumulative GC dose in patients with GCA has been shown to be associated with an increased risk of GC-related adverse events (AEs). 12 A similar association between cumulative GC exposure and burden of GC-related AEs and comorbidities also exists in patients with rheumatoid arthritis. 15 Prior studies have demonstrated the significant economic burden of GCA in the United States. A prior healthcare cost analysis reported that patients with GCA experience substantially higher healthcare costs (> USD $16,000 more) in the first year following diagnosis than patients without GCA. 16 GCA was identified as a major contributor to the USD $150 million in annual hospitalization costs associated with vasculitis in the United States. 17 A model-based study projected that from 2015 to 2050, the estimated costs associated with GCA-related visual impairments and steroid-induced fractures will reach USD $76 billion and USD $6 billion, respectively. 18 However, limited data exist specifically on GC-related healthcare costs in patients with GCA. The objective of this analysis was to quantify the healthcare expenditures associated with potential oral GC (OGC)-related AEs in patients with GCA across levels of cumulative OGC dose.
Methods

Data Source
This study used administrative healthcare claims from the US-based IBM MarketScan Commercial and Medicare Supplemental databases from January 1, 2008, to June 30, 2016. These databases include detailed costs, including both insurer-paid and patient out-of-pocket costs for medical services and prescriptions, use, and outcomes data for healthcare services performed in both inpatient and outpatient settings. All study data were deidentified and fully compliant with the Health Insurance Portability and Accountability Act of 1996; therefore, approval from an institutional review board was not required. Variables were measured using International Classification of Diseases, Clinical Modification (ICD-9-CM and/or ICD-10-CM) diagnosis and procedure codes, Healthcare Common Procedure Coding System codes, and National Drug Codes (NDC), as appropriate.
Patient Selection and Study Design
Patients who met the following criteria were identified: ≥ 1 inpatient or 2 outpatient nondiagnostic medical claims (≥ 7 days apart) with an ICD-9-CM diagnosis code for GCA in any diagnosis position between January 1, 2009, and June 30, 2014; ≥ 1 OGC drug prescription within 6 months after the GCA diagnosis date (index date = date of first OGC prescription on or after GCA diagnosis date) and a second OGC claim within 6 months after the first OGC claim; aged ≥ 50 years at the index date; ≥ 1 diagnostic workup claim (≤ 1 year pre-or postindex) for temporal artery biopsy, magnetic resonance angiography, computed tomography angiography, or positron emission tomography-computed tomography; ≥ 1 claim with a GCA diagnosis after the diagnostic workup claim; ≥ 12 months of continuous enrollment with medical and pharmacy benefits before the index date and before the GCA diagnosis date; no prior claims with a GCA diagnosis (≤ 1 year preindex); no tocilizumab or anti-tumor necrosis factor agent exposure during the 1 year before the index date; 2 years of continuous enrollment with medical and pharmacy benefits after the index date; and no nondiagnostic claims with a diagnosis of any other autoimmune disease (ie, ankylosing spondylitis, Crohn disease, juvenile idiopathic arthritis, polyarteritis nodosa, psoriatic arthritis, ulcerative colitis, granulomatosis with polyangiitis, systemic lupus erythematosus, and rheumatoid arthritis) 1 year before or 2 years after the index date. The exposure period for OGC use was defined as the first year after the index date, and the evaluation period for assessment of AEs and healthcare costs was defined as the first and second years after the index date; however, 2-year results are not presented here as the majority of OGC exposure occurred early in follow-up ( Figure 1 ). Cumulative dose of OGCs was measured during the 1-year postindex period based on the service date, days' supply, and strength of the NDC for OGC outpatient pharmacy claims and converted to prednisone-equivalent milligrams. Patients were stratified into 4 groups based on quartiles of the distribution of cumulative OGC exposure.
Outcomes
The incidence of potential OGC-related AEs was evaluated during the 1-year postindex period based on diagnosis codes for the following conditions in inpatient and outpatient medical claims: osteoporosis, nonvertebral or vertebral fracture, aseptic necrosis of bone, hospitalization for pneumonia or opportunistic or serious infection, hospitalization for myocardial infarction or stroke, type 2 diabetes, ulcer or gastrointestinal bleed, and gastrointestinal perforation. Patients who had evidence of chronic AEs in the preindex period were not eligible to contribute to the analyses of those AEs in the exposure period (osteoporosis, type 2 diabetes, ulcer/gastrointestinal bleed).
Payments on medical claims with a relevant diagnosis code for a potential AE (conditions described in the previous paragraph) in any position and pharmacy claims for AE-related medications during the evaluation period were considered as potential OGC-related AE costs; patients who had evidence of chronic AEs in the preindex period were not eligible to contribute to the analyses of the costs for those AEs in the exposure period. Preindex costs were also estimated using payments on all medical claims and pharmacy costs. Costs were captured in 2016 US dollars.
Statistical Analysis
Descriptive and bivariate statistics (eg, χ 2 tests and twosided, two sample Student's t-tests of means) were used to compare preindex characteristics and the proportion of patients with AEs between each of the 3 higher cumulative dose groups and the lowest cumulative dose group (> 0 to ≤ 2607 mg).
Generalized linear models with log-link and gamma distribution were fit to evaluate the association between OGC exposure (included as the log of continuous cumulative dose) and potential AE-related healthcare costs for all patients, controlling for patient characteristics. Covariates in the multivariable model were age group, sex, region, index year, AE in the preindex period, AE-related medication in the preindex period, hypothyroidism, ischemic heart disease, cancer, asthma/chronic obstructive pulmonary disease, Deyo-Charlson Comorbidity Index, number of unique diagnosis codes and unique NDCs, log of preindex costs, preindex OGC use, and an interaction between preindex OGC use and preindex OGC dose.
Mean and median predicted potential AE-related costs were displayed by dosing groups. P values of < 0.05 were considered statistically significant. SAS version 9.4 was used for all statistical analyses.
Results
Study Population and Patient Characteristics
Between January 1, 2009, and June 30, 2014, there were 16,868 patients with ≥ 1 inpatient or 2 outpatient claims with a GCA diagnosis. After applying the inclusion criteria, 1602 patients were included ( Figure 2 ). The mean cumulative OGC dose in the 1-year follow-up period was 5806 mg, with the most exposure (4438 mg) occurring in the first 6 months. Patients were categorized into groups based on OGC exposure, representing the following distributions: > 0 to ≤ 2607 mg, > 2607 to ≤ 4800 mg, > 4800 to ≤ 7200 mg, and > 7200 mg.
The mean age was 73.2 years (SD, 10.0 years), with no significant differences between the OGC dose groups (Table 1) . Most patients (68.9%) were female; the proportion of female patients was highest in the lowest cumulative OGC dose group compared with each of the other dose groups, but these differences were not statistically significant (P values = 0.06-0.07). Patients in the lowest cumulative OGC dose group had significantly higher preindex Deyo-Charlson Comorbidity Index scores compared with each of the 3 higher dose groups (Table 1) . Although preindex GCA-related blindness was rare (6.9% overall), it was significantly higher in the highest cumulative OGC dose group than in the lowest dose group (11.5% vs 4.7%; P < 0.001).
The mean all-cause preindex healthcare costs tended to be higher for lower dose groups, but there were no significant differences when comparing the lowest dose group with the 3 higher dose groups.
Potential OGC-Related AEs and Healthcare Costs
During the 1-year postindex period, a significantly higher proportion of patients in the highest cumulative OGC dose group had a potential OGC-related AE than those in the lowest dose group (45.3% vs 30.7%; P < 0.001; Figure 3 ). Unadjusted mean 1-year potential AE-related costs were higher for the highest cumulative dose group than for the lowest dose group (USD $5410 [SD, $20,908] vs USD $4972 [SD, $20,400]); however, the difference was not statistically significant. In the multivariable model, increasing cumulative OGC dose was associated with increasing potential AE-related healthcare costs ( Figure 4 ; Table 2) , with a cost ratio of 1.38 (95% CI, 1.16-1.64) per 1-unit increase in log of cumulative OGC dose (P < 0.001). The mean predicted costs for AEs increased gradually with the increase in cumulative dose from USD $4389 (SD, $5184) to USD $6609 (SD, $7281); median predicted costs increased from USD $2749 to USD $4447 from the lowest to highest OGC dose group. Among only patients with an AE (n = 584), the unadjusted mean and median 1-year potential AE-related costs were USD $12,818 (SD, $29,718) and USD $1844, respectively.
Discussion
In this large US claims-based real-world study of patients with GCA, the proportion of patients experiencing a potential OGC-related AE in the 1 year following initiation of OGCs increased with increasing cumulative OGC exposure. Higher cumulative OGC dose was significantly associated with increased AE-related healthcare costs. For patients exposed to a cumulative OGC dose of > 7200 mg over 1 year, the adjusted mean AE-related costs were estimated to be USD $2220 higher than for patients exposed to ≤ 2607 mg OGC.
Patients with lower cumulative OGC dose had significantly higher baseline comorbidities than those with higher cumulative OGC doses. This may reflect a cautionary approach by the treating physician of prescribing OGCs at a lower dose to avoid further complications in patients with significant comorbidities. In contrast, patients with blindness in the preindex period had the highest cumulative OGC doses. This may be due to a more aggressive approach by the treating physician to treat more severe GCA disease activity.
The trend in increased rates of potential OGC-related AEs with increasing cumulative OGC exposure in patients with GCA is consistent with previous findings from US healthcare claims databases and the UK Clinical Practice Research Datalink. 9, 12, 14 Prior studies have reported the association between the initial dose of prednisone and rates of AEs in patients with GCA. 19, 20 Our study adds to the evidence of the association between cumulative steroid dose and increased steroid-related AEs in patients with GCA. To our knowledge, this is the first study to evaluate costs of potential OGC-related AEs in patients with GCA using real-world data. A 2017 study also using US healthcare claims data demonstrated that in the year following diagnosis, estimated total healthcare costs were USD $16,431 more in patients with GCA than in patients without GCA. 16 Notably, the estimated increase in pharmacy costs in patients with GCA compared with controls during the first year after diagnosis was only USD $663; this was likely because steroids, the mainstay of treatment for GCA, are relatively inexpensive. However, our current study suggests that steroids can have a substantial effect on costs for patients with GCA, as higher cumulative OGC dose was associated with increased AEs and AE-related healthcare costs. The impact of cumulative OGC dose on AEs and AErelated costs is particularly important in GCA, given the chronic nature of the disease and the older age and increased frequency of comorbidities in the GCA patient population.
A strength of this study lies in the large real-world population of patients with GCA. Furthermore, this study adds to the literature on the association between cumulative OGC dose and potential OGC-related AEs and costs. This study also had limitations. The results of this analysis may not be generalizable to patients with GCA who have other insurance or no health insurance coverage. This study included new initiators as well as continuing users of OGCs. Mixing prevalent and incident user groups may lead to biases such as under-ascertainment of early events or "healthy user bias" due to prevalent users being adherent medication users. Due to the requirement for 2 years enrollment after the index date, those who died or became uninsured during those 2 years were excluded; this could have led to a healthy survivor effect. Medication dose was calculated based on the information on claims and may not accurately reflect actual use. Patients were assumed to have taken the medication as prescribed, but how the medication was consumed or whether it was taken as prescribed could not be confirmed. Although patients who had evidence of chronic AEs in the preindex period were not eligible to contribute to the analyses of the risks and/or costs of those AEs during the index period, it is possible that some of the risks and/or costs that were captured are attributable to other chronic or concurrent diseases.
As patients with GCA tend to be older and have significant comorbidities at the time of diagnosis, a quantitative understanding of GC exposure and GC-related AEs in patients with GCA is important for evaluating the benefit-risk of steroid-sparing agents in the treatment of GCA. Understanding the impact of cumulative GC exposure on healthcare costs associated with potential GC-related AEs is important for evaluating the role and position of steroid-sparing agents, such as tocilizumab, in treating GCA. 21 Patients with USD $0 were assigned USD $1 to be included in models. Covariates were age group, sex, region, index year, AE in the preindex period, AE-related medication in the preindex period, hypothyroidism, ischemic heart disease, cancer, asthma/COPD, Deyo-Charlson Comorbidity Index, number of unique diagnosis codes and unique National Drug Codes, log of preindex costs, preindex OGC use, and an interaction between preindex OGC use and preindex OGC dose. Abbreviations: AE, adverse event; OGC, oral glucocorticoid.
Conclusions
Rates of potential OGC-related AEs in patients with GCA tended to increase with an increase in cumulative OGC dose, which resulted in increased healthcare costs. These results highlight the need for efficacious therapies to treat GCA that reduce the exposure to and potential risks associated with OGCs. 
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